AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12069174 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 25 L x min(‐1) (PSbud25)
Number of subjects: 8
Study 12069174 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 microg budesonide PulmoSphere inhaled from Eclipse DPI at target PIF of 50 L x min(‐1) (PSbud50)
Number of subjects: 8
Study 12069174 — intervention group
Group type: COMPARATOR
Intervention: 800 microg of pelletized budesonide from Pulmicort Turbuhaler at 60 L x min(‐1) (THbud60)
Number of subjects: 8
Study 10417522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment with diisopropyl adipate
Number of subjects: 16
Study 10417522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment without diisopropyl adipate
Number of subjects: 16
Study 10417522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Betamethasone 17alpha-valerate ointment
Number of subjects: 16
Study 10417522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% Calcipotriol ointment
Number of subjects: 16
Study 10417522 — intervention group
Group type: COMPARATOR
Intervention: Vehicle controls for tacrolimus and betamethasone
Number of subjects: 16
Study 7752328 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin‐E1
Number of subjects: 10
Study 7752328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2405783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 15
Study 2405783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6994775 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg orally
Number of subjects: 14
Study 6994775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 mg intravenously
Number of subjects: 14
Study 6994775 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosing
Number of subjects: 14
Study 30341026 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeBag (10 minutes, 2x/day)
Number of subjects: 29
Study 30341026 — intervention group
Group type: COMPARATOR
Intervention: Control group (own dry eye treatment regimen)
Number of subjects: 29
Study 28386990 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine 100 U plus lixisenatide)
Number of subjects: 736
Study 25575084 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive decompression (MID)
Number of subjects: 96
Study 25575084 — intervention group
Group type: COMPARATOR
Intervention: X-Stop
Number of subjects: 96
Study 23644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg)
Number of subjects: 80
Study 23644132 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study 23644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 22107875 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 36
Study 22107875 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 36
Study 22107875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 36
Study 19252348 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxin treatment before and after
Number of subjects: 30
Study 19252348 — intervention group
Group type: COMPARATOR
Intervention: Control group (euthyroid healthy volunteers)
Number of subjects: 30
Study 19252348 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patient group to control group
Number of subjects: 30
Study 17255299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus interleukin 2 (IL-2)
Number of subjects: 0
Study 17255299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of IL-2 (either alone or in combination with IFN)
Number of subjects: 0
Study 17255299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IL-2 therapy
Number of subjects: 0
Study 15208972 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 70
Study 15208972 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (comparison group)
Number of subjects: 70
Study 11476927 — intervention group
Group type: COMPARATOR
Intervention: Short aortic cannula (aorta ascendens)
Number of subjects: 60
Study 11476927 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated aortic cannula (aorta descendens)
Number of subjects: 60
Study 9713297 — intervention group
Group type: COMPARATOR
Intervention: Epidoxorubicin (100 mg/m2) and Cyclophosphamide (600 mg/m2) on day 1 (group A)
Number of subjects: 73
Study 9713297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin and Cyclophosphamide plus GM-CSF (5 micrograms/kg/day) from days 3 to 12 (group B)
Number of subjects: 73
Study 9713297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin and Cyclophosphamide plus GM-CSF from days -6 to -3 (group C)
Number of subjects: 73
Study 8274110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume contrast computed tomographic scan of the brain plus trimodal evoked potentials
Number of subjects: 204
Study 8274110 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging of the brain
Number of subjects: 204
Study 2731771 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver cannula
Number of subjects: 168
Study 2731771 — intervention group
Group type: COMPARATOR
Intervention: Portex catheter
Number of subjects: 168
Study 2731771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (after failure of initial device)
Number of subjects: 168
Study 4713987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexachlorophane disinfection
Number of subjects: 0
Study 4713987 — intervention group
Group type: COMPARATOR
Intervention: Plain soap
Number of subjects: 0
Study 31411376 — intervention group
Group type: EXPERIMENTAL
Intervention: High acceptability (HA) custard
Number of subjects: 30
Study 31411376 — intervention group
Group type: COMPARATOR
Intervention: Low acceptability (LA) custard
Number of subjects: 30
Study 31411376 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with obesity
Number of subjects: 30
Study 31411376 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with normal weight
Number of subjects: 30
Study 27480340 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 28
Study 27480340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25218539 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic peritoneal dialysis catheter (PDC)
Number of subjects: 22
Study 25218539 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no PDC)
Number of subjects: 22
Study 25218539 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic PDC
Number of subjects: 22
Study 25218539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 22
Study 23258640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E + verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Number of subjects: 70
Study 23258640 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac
Number of subjects: 70
Study 21275979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (0.1 mg/kg, maximum 4 mg)
Number of subjects: 141
Study 21275979 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam (0.1 mg/kg, maximum 4 mg)
Number of subjects: 141
Study 19074920 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI biometry
Number of subjects: 70
Study 19074920 — intervention group
Group type: EXPERIMENTAL
Intervention: A-scan echography
Number of subjects: 70
Study 16401473 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 178
Study 16401473 — intervention group
Group type: COMPARATOR
Intervention: Gallbladders left in situ
Number of subjects: 178
Study 15510707 — intervention group
Group type: COMPARATOR
Intervention: NPSV at patient's comfort (C)
Number of subjects: 23
Study 15510707 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSV at physiological setting (PH)
Number of subjects: 23
Study 11794169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 263
Study 11794169 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 263
Study 9442424 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (Total, Colgate)
Number of subjects: 40
Study 9442424 — intervention group
Group type: COMPARATOR
Intervention: Supragingival plaque control
Number of subjects: 40
Study 7954041 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg od, increased to 8 mg od if DBP > 90 mmHg)
Number of subjects: 49
Study 7954041 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (120 mg [60 mg bid], increased to 360 mg [180 mg bid] if DBP > 90 mmHg)
Number of subjects: 49
Study 3312113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg OD
Number of subjects: 98
Study 3312113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg OD
Number of subjects: 98
Study 3312113 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 160 mg bid
Number of subjects: 98
Study 30009968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan therapy directed to the patient's face for five minutes
Number of subjects: 40
Study 30009968 — intervention group
Group type: COMPARATOR
Intervention: Fan therapy directed to the patient's legs (control group)
Number of subjects: 40
Study 27506635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of ezetimibe 10 mg plus rosuvastatin (5, 10, or 20 mg daily)
Number of subjects: 407
Study 27506635 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin alone (5, 10, or 20 mg daily)
Number of subjects: 407
Study 24664228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov circular fixator (IL)
Number of subjects: 58
Study 24664228 — intervention group
Group type: COMPARATOR
Intervention: Locked intramedullary nailing (IM)
Number of subjects: 58
Study 22342928 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 379
Study 22342928 — intervention group
Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 379
Study 20213795 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP-apheresis plus standard treatment
Number of subjects: 132
Study 20213795 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 132
Study 18725832 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based educational program on colorectal cancer screening
Number of subjects: 199
Study 15932816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (N=23)
Number of subjects: 55
Study 15932816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 55
Study 11909901 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 12
Study 11909901 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 12
Study 11909901 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from conventional to risperidone
Number of subjects: 12
Study 11909901 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from risperidone to conventional
Number of subjects: 12
Study 11464953 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (25, 60, 150, 400 or 1000 microg/day)
Number of subjects: 25
Study 11464953 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (doses >150 microg/day)
Number of subjects: 25
Study 11464953 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF
Number of subjects: 25
Study 11464953 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuBDNF (up to 150 microg/day)
Number of subjects: 25
Study 11464953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10179580 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutionary artificial neural networks (EANN)
Number of subjects: 0
Study 8443479 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 17
Study 8443479 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 17
Study 8443479 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both insulins
Number of subjects: 17
Study 3533566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dihydroergotamine (DHE)
Number of subjects: 30
Study 3533566 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dihydroergotamine (DHE)
Number of subjects: 30
Study 3533566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29408561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supplemental vitamin D3 (2000 IU/day)
Number of subjects: 771
Study 29408561 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 g/day)
Number of subjects: 771
Study 29408561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 771
Study 29071929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 60
Study 29071929 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 25479227 — intervention group
Group type: EXPERIMENTAL
Intervention: 940nm diode laser treatment
Number of subjects: 27
Study 25479227 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency therapy
Number of subjects: 27
Study 24669646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 0.2 mg + I/V fentanyl 2 microg/Kg
Number of subjects: 60
Study 24669646 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo + I/V fentanyl 2 microg/Kg
Number of subjects: 60
Study 20739418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA and HGI diet (HS/HGI)
Number of subjects: 548
Study 20739418 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA and HGI diet (HM/HGI)
Number of subjects: 548
Study 20739418 — intervention group
Group type: EXPERIMENTAL
Intervention: HM and LGI diet (HM/LGI)
Number of subjects: 548
Study 20739418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat and HGI diet (LF/HGI)
Number of subjects: 548
Study 20739418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat and LGI diet (LF/LGI)
Number of subjects: 548
Study 20739418 — intervention group
Group type: COMPARATOR
Intervention: SFA reduction
Number of subjects: 548
Study 20739418 — intervention group
Group type: COMPARATOR
Intervention: Fat reduction
Number of subjects: 548
Study 18294508 — intervention group
Group type: EXPERIMENTAL
Intervention: secretin-stimulated ePFT
Number of subjects: 24
Study 18294508 — intervention group
Group type: COMPARATOR
Intervention: Dreiling PFT
Number of subjects: 24
Study 16188207 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax oil (60 g)
Number of subjects: 30
Study 16188207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (60 g)
Number of subjects: 30
Study 16188207 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (< 1% omega‐3 fatty acids)
Number of subjects: 30
Study 12816171 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril (32.5-35.0 mg/day)
Number of subjects: 3164
Study 10816235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 10
Study 10816235 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized dermabrasion
Number of subjects: 10
Study 10816235 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 10
Study 8788540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic with harassment
Number of subjects: 31
Study 8788540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor task
Number of subjects: 31
Study 8788540 — intervention group
Group type: COMPARATOR
Intervention: Both stressor groups
Number of subjects: 31
Study 31421664 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallot (3g per day) and cetirizine (10 mg once daily)
Number of subjects: 16
Study 31421664 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10 mg once daily) and placebo capsules
Number of subjects: 16
Study 29891614 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Strengthening Programme (Copenhagen Adduction exercise), performed three times per week during preseason (6-8 weeks) and once per week during competitive season (28 weeks)
Number of subjects: 652
Study 29891614 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training)
Number of subjects: 652
Study 29891614 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Strengthening Programme
Number of subjects: 652
Study 29183775 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone pills (60 mg genistein, 60 mg daidzein, 16.6 mg glycitein)
Number of subjects: 197
Study 29183775 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 197
Study 27849214 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Slim Soft toothbrush
Number of subjects: 70
Study 27849214 — intervention group
Group type: COMPARATOR
Intervention: Curaprox CS5460 toothbrush
Number of subjects: 70
Study 23412304 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted rehabilitation training
Number of subjects: 60
Study 23216922 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback + Advice group (FA) - personal genetic test result for FTO gene + leaflet with weight control advice
Number of subjects: 800
Study 23216922 — intervention group
Group type: COMPARATOR
Intervention: Advice Only group (AO) - leaflet with simple weight control advice
Number of subjects: 800
Study 23216922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FA and AO)
Number of subjects: 800
Study 23216922 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback + Advice group (FA)
Number of subjects: 800
Study 18245967 — intervention group
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate/tobramycin
Number of subjects: 306
Study 18245967 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone/tobramycin
Number of subjects: 306
Study 16547078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient light reduction
Number of subjects: 188
Study 14575666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of hypertonic saline (two injections)
Number of subjects: 2
Study 14575666 — intervention group
Group type: COMPARATOR
Intervention: Unilateral injection of hypertonic saline (one injection)
Number of subjects: 2
Study 10714088 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial gastrectomy
Number of subjects: 10
Study 10714088 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 10
Study 10202506 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine mouthwash
Number of subjects: 26
Study 10202506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8263311 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 136
Study 8263311 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 136
Study 3964515 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat conservation during and after surgery (warming fresh gases, i.v. fluids, warmed cotton padding, metallized plastic sheet)
Number of subjects: 0
Study 3964515 — intervention group
Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 0
Study 30525844 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 66
Study 30525844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 26809813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg per day for 7 days)
Number of subjects: 239
Study 26809813 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (60 mg/kg up to 2 g per day for 7 days)
Number of subjects: 239
Study 24698577 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS) - group A
Number of subjects: 50
Study 24698577 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking DHS (Combi plate) - group B
Number of subjects: 50
Study 23029966 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training group
Number of subjects: 60
Study 23029966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Repetition (VR)
Number of subjects: 0
Study 20380778 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 0
Study 20380778 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 0
Study 18385577 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent absorbent acrylic dressing (TAAD)
Number of subjects: 72
Study 16612101 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Balloon Endometrial Ablation (TBEA)
Number of subjects: 44
Study 16612101 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel Intrauterine System (LNG-IUS)
Number of subjects: 44
Study 12941712 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 0
Study 12941712 — intervention group
Group type: COMPARATOR
Intervention: Metformin intervention
Number of subjects: 0
Study 11072284 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient nursing case management for cardiovascular disease
Number of subjects: 0
Study 8774269 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplement (5 g of creatine plus 1 g of glucose)
Number of subjects: 34
Study 8774269 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo (6 g of glucose)
Number of subjects: 34
Study 1377412 — intervention group
Group type: COMPARATOR
Intervention: DDAVP infusion
Number of subjects: 0
Study 6235582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial extract
Number of subjects: 20
Study 6235582 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 28734553 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII)
Number of subjects: 794
Study 28734553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower adherence to Mediterranean diet (MeDiet)
Number of subjects: 794
Study 28734553 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DII score
Number of subjects: 794